Danger of co-administration ferric carboxymaltose and denosumab: hypophosphatemia
Abstract Both denosumab-induced hypocalcemia and ferric carboxymaltose infusion-related hypophosphatemia have been extensively documented. There are significant risks associated with combining ferric carboxymaltose parenteral infusions and denosumab, including potentially life-threatening electrolyt...
Saved in:
Main Authors: | Aysun Seker, Nurdan Senturk Durmus |
---|---|
Format: | Article |
Language: | English |
Published: |
SpringerOpen
2025-01-01
|
Series: | The Egyptian Journal of Internal Medicine |
Subjects: | |
Online Access: | https://doi.org/10.1186/s43162-025-00406-z |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The experiences of ferric carboxymaltose desensitization and provocation
by: Fatma Dindar Çelik, MD, et al.
Published: (2025-02-01) -
Eligibility Criteria for Ferric Carboxymaltose in Women with Iron Deficiency in Obstetrics: An Algerian Expert Consensus
by: Rachida Aouameur, et al.
Published: (2024-12-01) -
Efficacy and safety of intravenous ferric carboxymaltose in the treatment of Restless Legs Syndrome: a systematic review and meta-analysis
by: Ayesha Khan, et al.
Published: (2025-01-01) -
Comprehensive Metabolomic Profiling in Adults with X-Linked Hypophosphatemia: A Case-Control Study
by: Luis Carlos López-Romero, et al.
Published: (2024-12-01) -
Findings of some biochemical and haematological in cows with hypophosphatemia and effect of phosphorous in treatment
by: Mahmut Ok, et al.